Markets & Regulations

Getty Images ©

AbbVie feels biosimilar impact on Humira sales

By Ben Hargreaves

In first quarter 2023 financials, the company reported a drop in net revenue of close 10%, as the impact of Humira biosimilar entry onto the market begins to bite.

Pic:getty/stocktrekimages

bluebird bio submits BLA for sickle cell disease gene therapy

By Rachel Arthur

bluebird bio has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD).

© Getty Images

Adcendo raises $34 million to fund ADC treatments for sarcoma

By Jonathan Smith


The Danish biotech Adcendo has bagged a Series A extension round of €31 million ($33.8 million), taking its Series A winnings so far to €82 million ($89.5 million). The round will bankroll the development of Adcendo’s pipeline of antibody-drug...

Exterior of new German logistics hub © UPS Healthcare

UPS Healthcare opens logistics facility in Germany

By Jane Byrne

UPS Healthcare says its first dedicated healthcare logistics facility in Giessen, Germany is now up and running. Up to 150 jobs have been created as a result of this operation, added the provider.

The extra MHRA funding will help accelerate patient access to new treatments, says the government. Pic: getty/221A

MHRA gets £10m boost from UK government

By Rachel Arthur

The UK Medicines and Healthcare products Regulatory Agency (MHRA) will receive £10m ($12m) in extra government funding over the next two years: targeted at helping the agency adapt post-Brexit and accelerating routes for bringing new medicines onto the...

© GettyImages/ipopba

Urgent action needed to reduce high costs of gene therapies

By Jane Byrne

The extremely high costs of gene therapies are unsustainable, and a global commitment to affordable, equitable access to these treatments is urgently needed, concluded the organising committee of a conference on human genome editing.

Pic:getty/maskot

Sanofi to acquire Provention Bio for $2.9bn

By Rachel Arthur

Sanofi will acquire US-based Provention Bio: gaining Tzield (teplizumab-mzwv), which was approved by the FDA last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes.